{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:28:17Z","timestamp":1786987697501,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.diabres.2025.112338","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T18:56:09Z","timestamp":1750704969000},"page":"112338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mortality, kidney, and safety outcomes with SGLT2 inhibitors versus DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids: a real-world exploratory study"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-3143","authenticated-orcid":false,"given":"Meir","family":"Schechter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yovel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Fishkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Aharon-Hananel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112338_b0005","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2025.112338_b0010","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112338_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.diabres.2025.112338_b0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the american college of cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.diabres.2025.112338_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.diabres.2025.112338_b0030","unstructured":"Yasir M, Goyal A, Sonthalia S (2025) Corticosteroid Adverse Effects. In: StatPearls. StatPearls Publishing, Treasure Island (FL)."},{"key":"10.1016\/j.diabres.2025.112338_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.diabres.2025.112338_b0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0055","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0060","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with Chronic Kidney Disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0070","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors as Enablers of Chronic Glucocorticoid Therapy","volume":"2","author":"Kahwash","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.diabres.2025.112338_b0075","doi-asserted-by":"crossref","first-page":"e2962","DOI":"10.1210\/clinem\/dgac164","article-title":"Association between SGLT2 inhibitors vs DPP4 inhibitors and renal outcomes among patients with type 2 diabetes","volume":"107","author":"Au","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.diabres.2025.112338_b0080","first-page":"1153","article-title":"Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease","volume":"18","author":"Melzer Cohen","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.diabres.2025.112338_b0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ndt\/gfae158","article-title":"Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes","volume":"40","author":"Suzuki","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.diabres.2025.112338_b0090","author":"Idris","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2025.112338_b0095","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/dom.14437","volume":"23","author":"Idris","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2025.112338_b0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12933-021-01281-y","article-title":"From glucose lowering agents to disease\/diabetes modifying drugs: a \u201cSIMPLE\u201d approach for the treatment of type 2 diabetes","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.diabres.2025.112338_b0105","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ije\/dyt013","article-title":"A U-shaped relationship between haematocrit and mortality in a large prospective cohort study","volume":"42","author":"Boffetta","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.diabres.2025.112338_b0110","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/JU.0000000000002437","article-title":"Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy","volume":"207","author":"Ory","year":"2022","journal-title":"J. Urol."},{"key":"10.1016\/j.diabres.2025.112338_b0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.diabres.2025.112338_b0120","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.diabres.2025.112338_b0125","doi-asserted-by":"crossref","unstructured":"Koshino A, Schechter M, Chertow GM, et al (2023) Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM evid 2:EVIDoa2300049. DOI: 10.1056\/EVIDoa2300049.","DOI":"10.1056\/EVIDoa2300049"},{"key":"10.1016\/j.diabres.2025.112338_b0130","unstructured":"Organization WH (2011) Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity."},{"key":"10.1016\/j.diabres.2025.112338_b0135","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.diabres.2025.112338_b0140","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112338_b0145","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112338_b0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-021-01362-y","article-title":"Cardiorenal outcomes with sodium\/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence","volume":"20","author":"Schechter","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.diabres.2025.112338_b0155","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/dom.13209","article-title":"Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease","volume":"20","author":"Gerards","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2025.112338_b0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12902-020-00561-0","volume":"20","author":"Klarskov","year":"2020","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.diabres.2025.112338_b0165","doi-asserted-by":"crossref","DOI":"10.1111\/dom.16221","article-title":"Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high-dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia","author":"Ikeda","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2025.112338_b0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015905","article-title":"Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France","volume":"7","author":"B\u00e9nard-Laribi\u00e8re","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2025.112338_b0175","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1111\/dom.15942","article-title":"Representation of women in randomized controlled trials of novel antidiabetic drugs: a cohort study","volume":"26","author":"Aharon-Hananel","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2025.112338_b0180","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","article-title":"Adverse effects of SGLT2 inhibitors on bone health","volume":"14","author":"Blau","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.diabres.2025.112338_b0185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12902-024-01575-8","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.diabres.2025.112338_b0190","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","article-title":"Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.diabres.2025.112338_b0195","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.diabres.2025.112338_b0200","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Accessed 1 May 2025."},{"key":"10.1016\/j.diabres.2025.112338_b0205","article-title":"Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies","volume":"10600280241312432","author":"Aboukaoud","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.diabres.2025.112338_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(23)00009-8","article-title":"Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial","author":"Schechter","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2025.112338_b0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/ndt\/gfz053","article-title":"Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies","volume":"34","author":"Rangaswami","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.diabres.2025.112338_b0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.1983.03340010031024","article-title":"Causes of death after kidney transplantation","volume":"250","author":"Washer","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2025.112338_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle Trial assessing the effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney Disease","author":"Bakker","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.diabres.2025.112338_b0230","unstructured":"Renal Lifecycle Trial \u2013 Renal lifecycle trial. https:\/\/renal-lifecycle.com\/en\/home-en\/. Accessed 4 Mar 2025."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725003523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725003523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:03:52Z","timestamp":1753909432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725003523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":46,"alternative-id":["S0168822725003523"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112338","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality, kidney, and safety outcomes with SGLT2 inhibitors versus DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids: a real-world exploratory study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112338"}}